Vaccine. 2022 Feb 14:S0264-410X(22)00196-7. doi: 10.1016/j.vaccine.2022.02.052. Online ahead of print.
High vaccine reactogenicities may reflect stronger immune responses, but the epidemiological evidence for coronavirus disease 2019 (COVID-19) vaccines is sparse and inconsistent. We observed that a fever of ≥38℃ after two doses of the BNT162b2 vaccine was associated with higher severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike IgG titers.